RAUltragenyx Pharmaceutical RARE · NASDAQ
$16.02 +6.30% (+$0.95)
- Market cap
- $1.58B
- Enterprise value
- $2.66B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 2.2x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -53.8%
- Bruto marža
- 83.1%
- Neto marža
- -81.8%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -
- Beta
- 0.32
- Free float
- 96.1%
O podjetju
Ultragenyx Pharmaceutical is a biotechnology company focused on developing innovative therapeutic options for rare genetic diseases. The company specializes in developing drugs that target specific genetic mutations or metabolic pathways that cause various rare diseases, including genetic disorders that affect metabolism, growth, and development. Ultragenyx focuses on conditions for which there are limited available treatment options and strives to improve the lives of patients with these diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Emil D. Kakkis
Employees
1,371
Headquarters
Novato
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke